Synartro

Synartro is a Swedish research and development company focused on creating innovative treatments for osteoarthritis (OA) by utilizing patented drug delivery technology in conjunction with established medications. Its lead program, SYN321, features a novel therapy that combines diclofenac, a nonsteroidal anti-inflammatory drug, with hyaluronan to enhance pain relief for knee OA, a condition that affects many patients inadequately. Synartro aims to improve treatment efficacy through local injection methods that ensure sustained drug release while minimizing systemic side effects, thereby enabling clinicians to potentially slow or halt disease progression. The company is positioned to expand its offerings beyond knee OA, addressing a significant unmet need in the management of osteoarthritis.